Drug Profile
Research programme: cancer fatigue therapeutics - Dimerix Bioscience
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Dimerix Bioscience
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Fatigue
Highest Development Phases
- No development reported Fatigue
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Fatigue in Australia
- 05 Aug 2016 Research programme: cancer fatigue therapeutics - Dimerix Bioscience is available for licensing as of 05 Aug 2016. http://dimerix.com/
- 05 Aug 2016 Early research in Fatigue in Australia (unspecified route)